Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations

References

• . Guyatt GH, Eikelboom JW, Gould MK, ; American College of Chest Physicians. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e185S–e194S
   Google Scholar
• . You JJ, Singer DE, Howard PA, ; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e531S–e575S
   PubMed Web of Science ®Google Scholar
• . Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e120S–e151S
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Dahl OE, Rosencher N, . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–956
   PubMed Web of Science ®Google Scholar
• . Ginsberg JS, Davidson BL, Comp PC, . Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Dahl OE, Rosencher N, . Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–2185
   PubMed Web of Science ®Google Scholar
• . Turpie AG, Lassen MR, Davidson BL, . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673–1680
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Borris LC, Friedman RJ, . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775
   PubMed Web of Science ®Google Scholar
• . Kakkar AK, Brenner B, Dahl OE, . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Ageno W, Borris LC, . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, . Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Flaker GC, Eikelboom JW, Shestakovska O, . Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin k antagonist treatment (AVERROES) trial. Stroke. 2012;43(12):3291–3297
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–2696
   PubMed Web of Science ®Google Scholar
• . Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172(8):623–631; discussion 631–623
   PubMedGoogle Scholar
• . Schulman S, Kearon C, Kakkar AK, . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352
   PubMed Web of Science ®Google Scholar
• . Bauersachs R, Berkowitz SD, Brenner B, . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510
   PubMed Web of Science ®Google Scholar
• . Büller HR, Prins MH, Lensin AW, . Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297
   PubMed Web of Science ®Google Scholar
• . Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2012
   Google Scholar
• . Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–252
   PubMed Web of Science ®Google Scholar
• . Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM; Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492–497
   PubMed Web of Science ®Google Scholar
• . Holbrook A, Schulman S, Witt DM, ; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e152S–e184S
   PubMed Web of Science ®Google Scholar
• . Denas G, Marzot F, Offelli P, . Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. J Thromb Thrombolysis. 2009;27(3):340–347
   PubMed Web of Science ®Google Scholar
• . Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Ann Rev Pharmacol Toxicol. 2012;52:79–99
   PubMed Web of Science ®Google Scholar
• . Moore TJ, Cohen MR, Furberg CD. Anticoagulants the leading reported drug risk in 2011. New data from 2011 Quarter 3–4. Institute for Safe Medication Practices: QuarterWatch. 2012. http://www.ismp.org/quarterwatch/pdfs/2011Q4.pdf. Accessed November 4, 2012
   Google Scholar
• . Pradaxa [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals, Inc.; 2011
   Google Scholar
• . Eikelboom JW, Wallentin L, Connolly SJ, . Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372
   PubMed Web of Science ®Google Scholar
• . Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579
   PubMed Web of Science ®Google Scholar
• . van Ryn J, Stangier J, Haertter S, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127
   PubMed Web of Science ®Google Scholar
• . Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–224
   PubMed Web of Science ®Google Scholar
• . Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259–268
   PubMed Web of Science ®Google Scholar
• . Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor Vila (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119(9):2172–2174
   PubMed Web of Science ®Google Scholar
• . Kaatz S, Kouides PA, Garcia DA, . Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87( suppl 1):S141–S145
   PubMed Web of Science ®Google Scholar
• . Peacock WF, Gearhart MM, Mills RM. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012;35(12):730–737
   PubMed Web of Science ®Google Scholar
• . Escolar G, Arellano-Rodrigo E, Reverter JC, . Coagulation factor concentrates restore alterations in hemostasia induced by a high dose of apixaban: studies in vitro with circulating human blood. Blood. 2012;120(21):2263
   Google Scholar
• . van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J. In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. Blood. 2012;120(21):3418
   Google Scholar
• . Hollenbach SJ, Lu G, Tan S, . PRT064445 but not recombinant FVIIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model. Blood. 2012;120(21):3414
   Web of Science ®Google Scholar
• . Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399
   PubMed Web of Science ®Google Scholar
• . Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412–421
   PubMed Web of Science ®Google Scholar
• . Raghavan N, Frost CE, Yu Z, . Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81
   PubMed Web of Science ®Google Scholar
• . Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954–2962
   PubMed Web of Science ®Google Scholar